Dan Leonard
Stock Analyst at Wells Fargo
(3.94)
# 681
Out of 4,412 analysts
194
Total ratings
54.17%
Success rate
7.7%
Average return
Main Sectors:
28 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RHP Ryman Hospitality Properties | Maintains: Overweight | $125 → $133 | $107.13 | +24.15% | 3 | Mar 21, 2024 | |
| CERT Certara | Maintains: Neutral | $17 → $20 | $17.08 | +17.10% | 7 | Mar 1, 2024 | |
| BIO Bio-Rad Laboratories | Maintains: Buy | $395 → $420 | $277.11 | +51.56% | 15 | Feb 16, 2024 | |
| RVTY Revvity | Downgrades: Neutral | $105 → $125 | $105.02 | +19.02% | 1 | Jan 16, 2024 | |
| TECH Bio-Techne | Initiates: Buy | $80 | $64.51 | +24.01% | 9 | Dec 7, 2023 | |
| FLGT Fulgent Genetics | Initiates: Neutral | $35 | $20.58 | +70.07% | 4 | Dec 7, 2023 | |
| A Agilent Technologies | Maintains: Outperform | $160 → $150 | $139.59 | +7.46% | 16 | Aug 16, 2023 | |
| ILMN Illumina | Maintains: Neutral | $225 → $200 | $124.73 | +60.35% | 10 | Aug 10, 2023 | |
| MRVI Maravai LifeSciences Holdings | Maintains: Neutral | $14 → $11 | $7.85 | +40.13% | 6 | Aug 8, 2023 | |
| NTRA Natera | Reiterates: Outperform | $70 | $94.04 | -25.56% | 7 | Aug 4, 2023 | |
| EXAS Exact Sciences | Maintains: Neutral | $75 → $90 | $58.78 | +53.11% | 9 | Aug 2, 2023 | |
| AVTR Avantor | Reiterates: Neutral | $24 | $24.08 | -0.33% | 5 | Jul 31, 2023 | |
| TMO Thermo Fisher | Upgrades: Outperform | $620 | $576.89 | +7.47% | 10 | Jul 13, 2023 | |
| CRL Charles River Laboratories International | Maintains: Outperform | $260 → $255 | $232.10 | +9.87% | 5 | May 12, 2023 | |
| GH Guardant Health | Maintains: Outperform | $60 → $55 | $18.19 | +202.36% | 7 | May 10, 2023 | |
| DHR Danaher | Maintains: Neutral | $300 → $270 | $246.82 | +9.39% | 11 | Apr 26, 2023 | |
| ADPT Adaptive Biotechnologies | Reiterates: Underperform | $7 | $2.75 | +154.55% | 2 | Feb 15, 2023 | |
| IQV IQVIA Holdings | Reiterates: Outperform | $265 | $235.48 | +12.54% | 6 | Feb 13, 2023 | |
| WAT Waters | Initiates: Neutral | $345 | $315.09 | +9.49% | 8 | Aug 25, 2022 | |
| ICLR ICON PLC | Initiates: Neutral | $260 | $304.14 | -14.51% | 5 | Aug 25, 2022 | |
| DGX Quest Diagnostics | Maintains: Equal-Weight | $160 → $145 | $139.50 | +3.94% | 9 | Feb 4, 2022 | |
| HOLX Hologic | Maintains: Overweight | $95 → $90 | $76.63 | +17.45% | 10 | Feb 3, 2022 | |
| QGEN Qiagen | Maintains: Equal-Weight | $60 → $62 | $42.30 | +46.10% | 2 | Dec 14, 2021 | |
| LH Laboratory Corporation of America Holdings | Maintains: Overweight | n/a | $204.17 | - | 7 | Dec 14, 2021 | |
| BRKR Bruker | Maintains: Equal-Weight | n/a | $81.26 | - | 6 | Nov 2, 2021 | |
| STVN Stevanato Group | Initiates: Overweight | n/a | $27.42 | - | 1 | Aug 10, 2021 | |
| MTD Mettler-Toledo International | Maintains: Equal-Weight | n/a | $1,255.24 | - | 6 | Jul 30, 2021 | |
| MYGN Myriad Genetics | Maintains: Hold | n/a | $19.80 | - | 7 | Nov 5, 2018 |
Ryman Hospitality Properties
Mar 21, 2024
Maintains: Overweight
Price Target: $125 → $133
Current: $107.13
Upside: +24.15%
Certara
Mar 1, 2024
Maintains: Neutral
Price Target: $17 → $20
Current: $17.08
Upside: +17.10%
Bio-Rad Laboratories
Feb 16, 2024
Maintains: Buy
Price Target: $395 → $420
Current: $277.11
Upside: +51.56%
Revvity
Jan 16, 2024
Downgrades: Neutral
Price Target: $105 → $125
Current: $105.02
Upside: +19.02%
Bio-Techne
Dec 7, 2023
Initiates: Buy
Price Target: $80
Current: $64.51
Upside: +24.01%
Fulgent Genetics
Dec 7, 2023
Initiates: Neutral
Price Target: $35
Current: $20.58
Upside: +70.07%
Agilent Technologies
Aug 16, 2023
Maintains: Outperform
Price Target: $160 → $150
Current: $139.59
Upside: +7.46%
Illumina
Aug 10, 2023
Maintains: Neutral
Price Target: $225 → $200
Current: $124.73
Upside: +60.35%
Maravai LifeSciences Holdings
Aug 8, 2023
Maintains: Neutral
Price Target: $14 → $11
Current: $7.85
Upside: +40.13%
Natera
Aug 4, 2023
Reiterates: Outperform
Price Target: $70
Current: $94.04
Upside: -25.56%
Exact Sciences
Aug 2, 2023
Maintains: Neutral
Price Target: $75 → $90
Current: $58.78
Upside: +53.11%
Avantor
Jul 31, 2023
Reiterates: Neutral
Price Target: $24
Current: $24.08
Upside: -0.33%
Thermo Fisher
Jul 13, 2023
Upgrades: Outperform
Price Target: $620
Current: $576.89
Upside: +7.47%
Charles River Laboratories International
May 12, 2023
Maintains: Outperform
Price Target: $260 → $255
Current: $232.10
Upside: +9.87%
Guardant Health
May 10, 2023
Maintains: Outperform
Price Target: $60 → $55
Current: $18.19
Upside: +202.36%
Danaher
Apr 26, 2023
Maintains: Neutral
Price Target: $300 → $270
Current: $246.82
Upside: +9.39%
Adaptive Biotechnologies
Feb 15, 2023
Reiterates: Underperform
Price Target: $7
Current: $2.75
Upside: +154.55%
IQVIA Holdings
Feb 13, 2023
Reiterates: Outperform
Price Target: $265
Current: $235.48
Upside: +12.54%
Waters
Aug 25, 2022
Initiates: Neutral
Price Target: $345
Current: $315.09
Upside: +9.49%
ICON PLC
Aug 25, 2022
Initiates: Neutral
Price Target: $260
Current: $304.14
Upside: -14.51%
Quest Diagnostics
Feb 4, 2022
Maintains: Equal-Weight
Price Target: $160 → $145
Current: $139.50
Upside: +3.94%
Hologic
Feb 3, 2022
Maintains: Overweight
Price Target: $95 → $90
Current: $76.63
Upside: +17.45%
Qiagen
Dec 14, 2021
Maintains: Equal-Weight
Price Target: $60 → $62
Current: $42.30
Upside: +46.10%
Laboratory Corporation of America Holdings
Dec 14, 2021
Maintains: Overweight
Price Target: n/a
Current: $204.17
Upside: -
Bruker
Nov 2, 2021
Maintains: Equal-Weight
Price Target: n/a
Current: $81.26
Upside: -
Stevanato Group
Aug 10, 2021
Initiates: Overweight
Price Target: n/a
Current: $27.42
Upside: -
Mettler-Toledo International
Jul 30, 2021
Maintains: Equal-Weight
Price Target: n/a
Current: $1,255.24
Upside: -
Myriad Genetics
Nov 5, 2018
Maintains: Hold
Price Target: n/a
Current: $19.80
Upside: -